C83.37 Diffuse large B-cell lymphoma, spleen

Name of the Condition

• Diffuse Large B-Cell Lymphoma, Spleen (ICD-10 Code: C83.37)

Summary

Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma that originates in B-cells, a type of white blood cell. It is characterized by rapidly growing tumors in the lymph nodes or other lymphoid tissues. This code specifies involvement of the spleen. DLBCL is one of the most common subtypes of non-Hodgkin lymphoma and can occur in various parts of the body.

Causes

The exact cause of DLBCL is not fully understood. It is believed to result from genetic mutations in B-cells, which may be triggered by factors such as previous infections (e.g., Epstein-Barr virus), immune system dysfunctions, or exposure to certain environmental agents. These mutations disrupt normal cell growth and division, leading to uncontrolled proliferation.

Risk Factors

• Advanced age (most common in older adults)
• Weakened immune system (e.g., from HIV, organ transplants, or immunosuppressive drugs)
• Family history of lymphoma
• Exposure to certain chemicals or radiation
• Chronic infections (e.g., hepatitis C)

Symptoms

• Swollen, painless lymph nodes (most often in the neck, armpit, or groin)
• Unexplained weight loss
• Fever
• Night sweats
• Fatigue
• Loss of appetite
• Abdominal pain or fullness (if spleen is enlarged)
• Easy bruising or bleeding (if spleen affects blood cell production)

Diagnosis

Diagnosis involves a combination of physical examination, imaging studies (e.g., CT or MRI scans) to assess spleen involvement, and biopsy of affected tissue. Blood tests may evaluate blood cell counts and organ function. A definitive diagnosis requires histopathological examination of tissue samples to confirm the presence of DLBCL and rule out other conditions.

Treatment Options

Treatment typically includes chemotherapy regimens, such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). For localized disease, radiation therapy may be used. In some cases, immunotherapy or stem cell transplantation may be considered, especially for relapsed or refractory disease. Treatment plans are tailored to the patient's overall health and disease stage.

Prognosis and Follow-Up

Prognosis varies based on factors like age, overall health, and response to treatment. Many patients achieve remission with standard therapy, but some may experience recurrence. Regular follow-up appointments, including physical exams and imaging, are essential to monitor for relapse or complications. Long-term surveillance helps detect late effects of treatment.

Complications

• Organ dysfunction due to tumor infiltration (e.g., spleen enlargement causing pain or reduced function)
• Increased risk of infections from impaired immune response
• Side effects from treatment, such as fatigue, nausea, or bone marrow suppression
• Potential for transformation to a more aggressive lymphoma in rare cases

Lifestyle & Prevention

• Maintain a balanced diet and regular exercise to support overall health during and after treatment.
• Avoid exposure to known carcinogens, such as tobacco or excessive radiation.
• Stay up-to-date with vaccinations, especially if immune function is compromised.
• Manage stress through relaxation techniques or support groups, as emotional well-being can impact recovery.

When to Seek Professional Help

Seek immediate medical attention if you experience:

• Sudden, severe abdominal pain or swelling
• Unexplained weight loss, fever, or night sweats lasting more than two weeks
• Persistent fatigue or weakness
• Easy bruising, bleeding, or signs of infection (e.g., fever, chills)

Tips for Medical Coders

Use code C83.37 when documenting diffuse large B-cell lymphoma with confirmed spleen involvement. Ensure clinical documentation specifies the site (spleen) to justify the code. Verify that the diagnosis aligns with histopathological findings and exclude other lymphoma subtypes or sites. Accurate coding supports appropriate treatment planning and resource allocation.